Document details for 'Duration of protection and humoral immunity induced by an adenovirus- vectored foot-and-mouth disease virus serotype A24 subunit vaccine in Holstein steers'

Authors Sitt, T., Kenney, M., Barrera, J., Pandya, M., Eckstrom, K., Warner, M., Pacheco, J.M., LaRocco, M., Palarea Albaladejo, J., Brake, D., Rieder, E., Arzt, J., Barlow, J.W. and Golde, W.T.
Publication details Vaccine 37, 6221-6231. Elsevier.
Publisher details Elsevier
Keywords Foot-and-mouth disease virus, replication-deficient human adenovirus vectored vaccine, FMDV A24/Cruzeiro/BRA/55, duration of immunity, cattle
Abstract The importance of an efficacious, long acting foot-and-mouth disease (FMD) vaccine is critical to control FMD. The human replication deficient adenovirus 5 (Ad5) empty capsid FMD virus (FMDV) platform (AdtFMD), is a promising new vaccine technology. Herein we describe three studies assessing the proportion of animals protected from clinical vesicular disease (foot lesions) following live-FMDV challenge by intradermolingual inoculation at 6 or 9 months following a single vaccination, and the potential effect of vaccination route (transdermal, intramuscular, subcutaneous) on clinical outcome. Results demonstrate that a single dose AdtA24 vaccination in cattle induced protection against clinical FMD at 6 months (100% transdermal, 80% intramuscular, and 60% subcutaneous) that waned by 9 months post-vaccination (33% transdermal and 20% intramuscular). Post-vaccination serum from immunized cattle (all studies) generally contained FMDV specific neutralizing antibodies by day 14. Overall, when specific Ig isotype responses were assessed, the number of IgG1 anti-FMDV antibody secreting cells detected in vaccinated steers compared to placebo-immunized controls was statistically significant (p=0.007). The decay in protective immunity over time may be a function of FMDV-specific antibody half-life due to loss of antibody secreting cells in circulation by four to five weeks post vaccination. These data reveal important performance characteristics of needle-free vaccination with a recombinant vectored subunit vaccine for FMDV.
Last updated 2019-09-16

Unless explicitly stated otherwise, all material is copyright © Biomathematics and Statistics Scotland.

Biomathematics and Statistics Scotland (BioSS) is formally part of The James Hutton Institute (JHI), a registered Scottish charity No. SC041796 and a company limited by guarantee No. SC374831. Registered Office: JHI, Invergowrie, Dundee, DD2 5DA, Scotland